This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

William Kiesman, Ph.D.
Chief Technology Officer at Alltrna


Dr. Kiesman has more than two decades of experience in the design, development, and manufacturing of small molecule and oligonucleotide therapeutics. Prior to joining Alltrna, he served as the Vice President and Head of Oligonucleotide and Small Molecule Development at Biogen. During his 24 years with the company, he was responsible for a wide range of activities from medicinal chemistry research and automated parallel synthesis to building both the chemical development and the end-to-end oligonucleotide development and manufacturing teams. Dr. Kiesman and his teams have supported dozens of small molecule and oligonucleotide clinical programs and played pivotal roles in the successful worldwide regulatory CMC approvals of Tecfidera® (dimethyl fumarate) in multiple sclerosis, Spinraza® (nusinersen) for spinal muscular atrophy and recently Qalsody® (tofersen) in ALS. He is co-author on more than 40 publications and patents and has contributed to five book chapters.

Agenda Sessions

  • Manufacturing Strategies for Chemically Modified tRNAs